Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM
Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM
Active, not recruiting · NCT06005012 · Registry updated 2026-07-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM | Digestive System Diseases, Fibrosis, Fibrosis, Liver, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cirrhosis of liver, fatty liver disease, liver disorder, metabolic dysfunction-associated steatotic liver disease | Active, not recruiting | Phase 2 | 2026-07-17 | NCT06005012 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| University of California, San Diego | 337 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| University of California, San Diego | La Jolla | United States | 38 |